On November 22, 2024, Justin Leong, Chief Product Officer at ResMed Inc's subsidiary, sold 6,160 shares of ResMed Inc (RMD, Financial). Following this transaction, the insider now owns 21,718 shares of the company. The details of this transaction can be found in the SEC Filing.
ResMed Inc is a global leader in connected devices and cloud-based software applications that help diagnose, treat, and manage sleep apnea, chronic obstructive pulmonary disease, and other respiratory conditions. The company’s innovative solutions aim to improve patient quality of life, reduce the impact of chronic disease, and lower healthcare costs.
Over the past year, Justin Leong has sold a total of 54,160 shares and has not purchased any shares. The insider transaction history for ResMed Inc indicates that there have been no insider buys and 32 insider sells over the same period.
On the day of the recent sale, shares of ResMed Inc were trading at $243.09, giving the stock a market cap of $36,088.266 million. The company's price-earnings ratio stands at 32.56, which is higher than the industry median of 28.98 but lower than the company’s historical median price-earnings ratio.
With a trading price of $243.09 and a GF Value of $269.56, ResMed Inc has a price-to-GF-Value ratio of 0.9, indicating that the stock is fairly valued based on its GF Value. The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on historical multiples, a GuruFocus adjustment factor, and future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
